Navigation Links
Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
Date:6/17/2011

Access retains its existing milestone and royalty structure for the territory.  

"The acceptance of MuGard submission is a critical step in receiving marketing approval for MuGard in China and South East Asian territories," said Phillip Wise, Vice President of Business Development and Strategy, Access Pharmaceuticals, Inc.  He continued, "We knew that the SFDA would perform a significant amount of due diligence before it would accept our MuGard submission.  Receiving the acceptance letter helps us, as a company, gauge more accurately the timeline to marketing approval.  We are pleased with RHEI and Jian An's ability to streamline the process thus far and their continued progress and commitment to advancing the marketing approval."  

About MuGard:MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About RHEI Pharmaceuticals:RHEI Pharmaceuticals is a specialty pharmaceutical company with operations in the U.S. and in China that acquires licenses, develops and commercializes in China proprietary drug therapies
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... voice on the recording was low and calm as the speaker ... with the human immunodeficiency virus (HIV) that causes AIDS: “My heart ... I was on the floor flat on my face boohooing, crying ... recording ended less than 10 minutes later. “Don’t feel like this ... is just God setting you up for something greater,” the anonymous ...
(Date:7/23/2014)... By Kathleen Doheny ... (HealthDay News) -- Weight-loss surgery appears to have an ... symptoms in women, according to a new study. ... a weight-loss surgery program reported having incontinence prior to ... their urinary symptoms either improved or disappeared, said study ...
(Date:7/23/2014)... By Amy Norton ... -- The timing of a girl,s first menstrual period may ... a new study suggests. Researchers have identified over ... of menarche -- a woman,s first menstrual period. The researchers ... a number of diseases ranging from type 2 diabetes to ...
(Date:7/23/2014)... genes have been focused on the regions of the ... the form of amino acids thus proteins. But just ... activator which controls the expression and activity of the ... the role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, ...
(Date:7/23/2014)... likelihood of forming false memories, according to research published ... Association for Psychological Science. , In a study conducted ... of California, Irvine and colleagues, sleep-deprived people who viewed ... false information about the photos were more likely to ... were those who got a full night,s sleep. , ...
Breaking Medicine News(10 mins):Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Sleep deprivation may increase susceptibility to false memories 2
... Hospitals that have better working conditions for nurses are ... to a recent report , led by researchers ... are the number six cause of death in the ... workforce in the nation's hospitals, are in a unique ...
... claimed to have developed super-oxidised water, which speeds up ... is made by passing it through a salt membrane ... fungi. ,The company claims that the solution ... ,We would welcome any safe effective treatment which could ...
... has found how medical science could employ aspirin and ... in certain high-risk individuals. ,The study ... Sanford Markowitz at the Ireland Cancer Center. ... mechanism by which the use of aspirin and nonsteroidal ...
... Army hospital here has conducted an accident victim's multiple organ ... to three individuals. ,The retrievals were conducted ... and the organs were transplanted Thursday on two patients at ... ,Donor Ramesh Chand, 60, whose two sons serve ...
... their birth, healthy babies will look you in the eye. ... 9 months, they will exchange smiles. If they ... to worry. ,There is a growing field ... increasingly looking for early signs in babies of autism, attention ...
... Chinese exporters. After the furore over pet food, it is ... under the scanner. ,The federal government has announced ... Food and Drug Administration decides whether the product contains diethylene ... fluid. ,The imports will be released only if ...
Cached Medicine News:Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 2Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 3Health News:Aspirin may Help to Prevent Colon Cancer in High-risk Individuals 2Health News:Army Hospital Conducts First Multiple Organ Retrieval and Transplantation 2Health News:Watch Out for Signs of Autism in Babies! 2Health News:Watch Out for Signs of Autism in Babies! 3Health News:US Halts Import of Chinese Toothpaste 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: